The CD1dhiCD5+CD19+ Bregs are thought to suppress immune responses during cancer immune surveillance by releasing anti-inflammatory mediators (IL-10) and expressing (co-) inhibitory molecules (PD-L1) [74]. This evidence concerns the gene CD274 and cancer.